Gilead Grabs MiroBio's Checkpoint Agonists For $405m
Another UK Biotech Swallowed Up
Just over a month after raising $97m in a series B round, Oxford University spinout MiroBio and its immune checkpoint agonists have been snapped up by Gilead Sciences.
